Happy to see that Replidyne, Inc. (Nasdaq: RDYN) began trading this morning at 11:00am! Next stop…approval for Orapem™!

• 101View 1 Comment...http://clsdf.com/2006/06/feather-in-colorados-cap/Feather+in+Colorado%27s+Cap2006-06-28+21%3A05%3A00admin

BioMed Realty Trust, Inc. (NYSE: BMR) a real estate investment trust focused on the life science industry has entered into an agreement to acquire Array BioPharma’s (Nasdaq: ARRY) approximately 150,000 square-foot, four-building campus in Boulder and 78,000 square-foot, two-building campus in Longmont. The transactions are $45.0 million for the Boulder campus and $20.8 million for [...]

• 100http://clsdf.com/2006/06/array-biopharma-pads-war-chest/Array+Biopharma+Pads+War+Chest2006-06-25+16%3A04%3A00admin

Replidyne, Inc. (Nasdaq: proposed RDYN) intends to offer up to Wall St. 5 million shares priced between $14 and $16 in next weeks highly anticipated IPO. What makes me exceedingly bullish on this offering is that unlike many biotech IPO’s that transpire in the midst of Phase II or III and sometimes even during Phase [...]

• 99http://clsdf.com/2006/06/replidyne-off-to-see-wall-street/Replidyne+Off+to+See+Wall+Street2006-06-23+21%3A55%3A00admin

GlobeImmune, Inc. announced the initiation of a Phase II clinical trial of GI-4000, for the treatment of early-stage pancreas cancer. GI-4000 is designed to activate the immune system against cancer cells containing a mutated protein called Ras that is found in 80-90% of pancreas tumors. In a recently completed Phase 1 study of end-stage pancreas [...]

• 98http://clsdf.com/2006/06/globeimmune-initiates-phase-ii-trial/GlobeImmune+Initiates+Phase+II+Trial2006-06-09+06%3A49%3A00admin

Myogen, Inc. (NASDAQ: MYOG) now has two candidates in Phase III trials, Ambrisentan and now Darusentan. The Darusentan trial will evaluate patients with resistant hypertension (RHTN). RHTN is the “the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic.” The primary [...]

• 97View 1 Comment...http://clsdf.com/2006/06/myogen-darusentan-enters-phase-iii/Myogen%3A+Darusentan+Enters+Phase+III2006-06-05+16%3A39%3A00admin

There are many reasons why here in Colorado we keep a careful eye on Macugen, no pun intended… OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced interim Phase II study results showing that injections of Macugen® resulted in better visual acuity outcomes in patients with macular edema due to central retinal vein occlusion compared with those receiving [...]

• 96http://clsdf.com/2006/06/positive-phase-ii-data-for-macugen%c2%ae/Positive+Phase+II+Data+for+Macugen%C2%AE2006-06-02+14%3A57%3A00admin